ALK inhibitors and checkpoint blockade: a cautionary tale of mixing oil with water?

Over the last decade, remarkable advances in therapeutic options led to improved outcomes in the treatment of advanced non-small cell lung cancer (NSCLC). Much of this is owed to a shift in categorizing NSCLC by a few histological subtypes to a more heterogeneous entity defined by distinct molecular subtypes.